The VC is funded mainly via Rigmora Biotech Investor One and Rigmora Biotech Investor Two, according to a June 27 press release. Both funds are part of Rigmora Holdings, a family office that manages ...

Although the SYMMETRY Phase IIb trial of the FGF21 analogue efruxifermin did not meet its primary endpoint at 36 weeks, ...

Pfizer will pay a $0.43 quarterly dividend on September 2, 2025, maintaining its 347-quarter streak of shareholder payouts.

Akero Therapeutics (NASDAQ: AKRO) Chief Development Officer Yale Catriona sold 1,633 shares of common stock on June 18, 2025, according to a Form 4 filing with the Securities and Exchange Commission.

Detailed price information for Rapt Therapeutics Inc (RAPT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Protagonist Therapeutics Inc (PTGX-Q) from The Globe and Mail including charting and trades.

Akero Therapeutics shares last traded at $43.15, with a volume of 76,195 shares trading hands. Specifically, Director G. Walmsley Graham bought 50,000 shares of Akero Therapeutics stock in a ...

Akero Therapeutics has a 1-year low of $17.86 and a 1-year high of $58.40. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25.

Akero Therapeutics, Inc. (NASDAQ:AKRO) is up 71.75% year-to-date. Overall AKRO ranks 4th on our list of the biotech stocks that are skyrocketing so far in 2025.

Analyst Ratings Published 01/29/2025, 04:55 PM 0 Jefferies raises Akero Therapeutics price target to $75 AKRO -3.65% ...

In addition, Akero Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the public offering price, less underwriting ...

In addition, Akero Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of shares of its common stock at the public offering price, less ...